A recurrent CHEK2 p.H371Y mutation is associated with breast cancer risk in Chinese women

Human Mutation

Volumn 32, Issue 9, 2011, Pages 1000-1003

  Liu, Yin ^a   Liao, Ji ^b   Xu, Ye ^a   Chen, Weiqiu ^a   Liu, Dongyun ^b   Ouyang, Tao ^a   Li, Jinfeng ^a   Wang, Tianfeng ^a   Fan, Zhaoqing ^a   Fan, Tie ^a   Lin, Benyao ^a   Xu, Xingzhi ^b   Xie, Yuntao ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CAPITAL NORMAL UNIVERSITY   (China)

Author keywords

CHEK2; Chinese women; Familial breast cancer; P.H371Y

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 2; DOXORUBICIN; ETOPOSIDE; PHOSPHOTRANSFERASE;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CHINESE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT DISEASE;

ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHECKPOINT KINASE 2; CHINA; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; RISK FACTORS;

EID: 80051685689     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21538     Document Type: Article

References (16)

1. Bartek J, Falck J, Lukas J. 2001. CHK2 kinase-a busy messenger. Nat Rev Mol Cell Biol 2:877-886.
2. Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH. 2004. Analysis of CHEK2 gene for ovarian cancer susceptibility. Gynecol Oncol 95:62-69.
3. Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA. 1999. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531.
4. Cai Z, Chehab NH, Pavletich NP. 2009. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol Cell 35:818-829.
5. Cao AY, Hu Z, Shao ZM. 2010. Mutation screening of breast cancer susceptibility genes in Chinese high-risk families: the results will develop the genetic testing strategy in China. Breast Cancer Res Treat 120:271-272.
6. Chen W, Yurong S, Liansheng N. 2008. Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population. Adv Ther 25:496-501.
7. Dufault MR, Betz B, Wappenschmidt B, Hofmann W, Bandick K, Golla A, Pietschmann A, Nestle-Kramling C, Rhiem K, Huttner C, von Lindern C, Dall P, Kiechle M, Untch M, Jonat W, Meindl A, Scherneck S, Niederacher D, Schmutzler RK, Arnold N. 2004. Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer 110:320-325.
8. Liede A, Narod SA. 2002. Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2. Hum Mutat 20:413-424.
9. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR CHEK2-Breast Cancer Consortium. 2002. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59.
10. Narod SA, Lynch HT. 2007. CHEK2 mutation and hereditary breast cancer. J Clin Oncol 25:6-7.
11. Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N; Breast Cancer Linkage Consortium. 2003. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet 72:1023-1028.
12. Sodha N, Mantoni TS, Tavtigian SV, Eeles R, Garrett MD. 2006. Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. Cancer Res 66:8966-8970.
13. Sodha N, Williams R, Mangion J, Bullock SL, Yuille MR, Eeles RA. 2000. Screening hCHK2 for mutations. Science 289:359.
14. Song CG, Hu Z, Yuan WT, Di GH, Shen ZZ, Huang W, Shao ZM. 2006. [CHEK2 c.1100delC may not contribute to genetic background of hereditary breast cancer from Shanghai of China]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23:443-445.
15. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG. 2008. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26, 000 patient cases and 27, 000 controls. J Clin Oncol 26:542-548.
16. Xu X, Tsvetkov LM, Stern DF. 2002. Chk2 activation and phosphorylation-dependent oligomerization. Mol Cell Biol 22:4419-4432.